Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

Myostatin and activin blockade by engineered follistatin results in hypertrophy and improves dystrophic pathology in mdx mouse more than myostatin blockade alone.

Iskenderian A, Liu N, Deng Q, Huang Y, Shen C, Palmieri K, Crooker R, Lundberg D, Kastrapeli N, Pescatore B, Romashko A, Dumas J, Comeau R, Norton A, Pan J, Rong H, Derakhchan K, Ehmann DE.

Skelet Muscle. 2018 Oct 27;8(1):34. doi: 10.1186/s13395-018-0180-z.

2.

Protein Engineering on Human Recombinant Follistatin: Enhancing Pharmacokinetic Characteristics for Therapeutic Application.

Shen C, Iskenderian A, Lundberg D, He T, Palmieri K, Crooker R, Deng Q, Traylor M, Gu S, Rong H, Ehmann D, Pescatore B, Strack-Logue B, Romashko A, Baviello G, Gill J, Zhang B, Meiyappan M, Pan C, Norton AW.

J Pharmacol Exp Ther. 2018 Aug;366(2):291-302. doi: 10.1124/jpet.118.248195. Epub 2018 May 11.

PMID:
29752426
3.

Expression of major histocompatibility complex class I proteins and their antigen processing chaperones in mouse embryonic stem cells from fertilized and parthenogenetic embryos.

Lampton PW, Crooker RJ, Newmark JA, Warner CM.

Tissue Antigens. 2008 Nov;72(5):448-57. doi: 10.1111/j.1399-0039.2008.01132.x. Epub 2008 Sep 5.

Supplemental Content

Loading ...
Support Center